secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001764013-23-000150
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C
--------------------------------------------------------------------------------

- Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.
- No significant changes in serum albumin or LDL-C at Day 29 (p>0.05), consistent with placebo-like profile.
- All doses well tolerated; only mild or moderate treatment-emergent adverse events observed.
- Company expects ~80% steady-state IgG reduction with continued weekly 600 mg dosing after 6-8 weeks.
- Immunovant says profile supports broad portfolio of first-in-class and best-in-class FcRn indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/0001764013-23-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/imvt-20231128.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer